Overview

Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status

Status:
NOT_YET_RECRUITING

Trial end date:
2030-03-01

Target enrollment:

Participant gender:

Summary

The aim of this trial is to assess the feasibility of EREG/AREG assessment as a clinical diagnostic standard, used to guide clinical decision making in right-PTL, RAS-wt aCRC. Further to this, the aim is to determine whether EREG/AREG status identifies right-PTL participants who will benefit from the addition of anti-EGFR therapy to first-line chemotherapy.

Phase:

PHASE4

Details

Lead Sponsor:

Gruppo Oncologico del Nord-Ovest

Collaborator:

Merck Serono International SA

Treatments:

Bevacizumab
Capecitabine
Cetuximab
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin